{"id":"hiv-immune-globulin-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This immunoglobulin product contains antibodies derived from HIV-infected or vaccinated donors that are pooled and processed into a solution for intravenous or intramuscular administration. It works by providing immediate, passive immunity through pre-formed antibodies that can neutralize HIV virions, enhance antibody-dependent cellular cytotoxicity (ADCC), and support the host's immune system in controlling HIV infection. This approach aims to augment the body's natural immune defenses against HIV.","oneSentence":"HIV immune globulin provides passive immunization by supplying antibodies against HIV to enhance immune response and potentially reduce viral load or transmission risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:44:05.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection (investigational)"},{"name":"HIV prevention or post-exposure prophylaxis (investigational)"}]},"trialDetails":[{"nctId":"NCT06652958","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-10-02","conditions":"HIV Infections","enrollment":102},{"nctId":"NCT07054931","phase":"PHASE2","title":"Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-05","conditions":"HIV","enrollment":48},{"nctId":"NCT06628570","phase":"NA","title":"Screening Strategies Among High-risk Populations for Anal Cancer","status":"RECRUITING","sponsor":"Lisa Flowers","startDate":"2024-12-16","conditions":"Neoplasms, HPV-Related Anal Squamous Cell Carcinoma","enrollment":500},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT05300035","phase":"PHASE2","title":"Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-11","conditions":"HIV/AIDS and Infections","enrollment":69},{"nctId":"NCT04871113","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-06-22","conditions":"HIV Infections","enrollment":62},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT01959672","phase":"PHASE2","title":"Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2013-09-06","conditions":"Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer","enrollment":11},{"nctId":"NCT04723602","phase":"PHASE1","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2021-01-06","conditions":"Ebola Virus Disease, Marburg Virus Disease","enrollment":32},{"nctId":"NCT02165267","phase":"PHASE1","title":"Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-08","conditions":"HIV Infections","enrollment":88},{"nctId":"NCT04578145","phase":"NA","title":"Community Based Screening for HIV Self Testing in FSW in 23 Priority Districts in Indonesia","status":"UNKNOWN","sponsor":"Kerti Praja Foundation","startDate":"2020-04-17","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":1522},{"nctId":"NCT01306682","phase":"PHASE2, PHASE3","title":"Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2011-03","conditions":"Influenza","enrollment":194},{"nctId":"NCT01403792","phase":"PHASE1","title":"A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2011-06","conditions":"Human Immunodeficiency Virus","enrollment":11},{"nctId":"NCT00503347","phase":"PHASE1","title":"Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Peregrine Pharmaceuticals","startDate":"2007-07","conditions":"Hepatitis C Virus, Hiv Infections","enrollment":24},{"nctId":"NCT00639938","phase":"PHASE3","title":"Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":722}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HIVIGLOB"],"phase":"phase_3","status":"active","brandName":"HIV immune globulin solution","genericName":"HIV immune globulin solution","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIV immune globulin provides passive immunization by supplying antibodies against HIV to enhance immune response and potentially reduce viral load or transmission risk. Used for HIV infection (investigational), HIV prevention or post-exposure prophylaxis (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}